Gavish-galilee Bio Applications Ltd.

Immpact-bio Ltd.

Gavish-galilee Bio Application Ltd.

Gideon Gross

Dvir Dahary

Merav Beiman

Alon Margalit

Will Gibson

William Gibson

William J Gibson

Adi Sharbi-Yunger

Yael Sagi

The present invention provides a method of identifying a target for preparing an inhibitory chimeric antigen receptor (iCAR) or a protective chimeric antigen receptor (pCAR) capable of preventing or attenuating undesired activation of an effector immune cell. Also provided are a list of iCAR targets, as well as vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.

Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)

The invention provides DNA molecules encoding a chimeric polypeptide comprising (a) a component of a MHC molecule capable of association on a cell surface with an endogenous MHC molecule component of the same class, and (b) an intracellular region of a signal transduction element capable of activating T cells. Component (a) may be a monomorphic component and is preferably beta 2-microglobulin, or a polymorphic class I or class II component. The signal transduction element (b) capable of activating T cells may be a component of T-cell receptor CD3, preferably the CD3 zeta (zeta) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. Immune cells such as a CTLs expressing said chimeric MHC molecules specifically eliminate or inactivate harmful T cells and are useful for treating graft rejection and autoimmune diseases.

Genetically-engineered MHC molecules

Growing community of inventors

Moshav Almagor, Israel

Gideon Gross